Why the study?
Guidelines recommend early intensive statins for high-risk patients to prevent ACS-related events, but inconsistent statin utilization in current practice remains an issue.
Despite established guideline recommendations, statins remain underutilized for secondary prevention after ACS, with utilization rates declining during follow-up and disparities evident among female and elderly patients.
Answers are grounded in this paper and cite their sources.
Statin underutilization after ACS persists with post-discharge declines and disparities; challenges guideline implementation and extends research on barriers and equity.
BACKGROUND: The early use of statin with intensive regimen has been recommended by the recent guidelines as the prevention of acute coronary syndrome (ACS) related events among the high-risk patients. Meanwhile, the inconsistent statin utilization for targeted patient in current practice is still an issue. AIM: This study aims to review the utilization rate of statin among patients with ACS. METHODS: A systematic search of relevant studies published between inceptions to June 2020 was conducted in PubMed. Patients and intervention domains were used to build up the searching formula. A study was eligible for inclusion if it was an original study of patients with ACS and it examined the utilization of statin. The risk of bias was assessed using Axis and NOS checklist. RESULTS: Among the 49 eligible studies, 38 were cohort studies while the others were cross-sectional studies. The utilization rate of statin at hospital admission ranged from 16% to 61% while 25% to 75% during the hospitalization. Of the total studies, 35 studies reported the statin rate at discharge ranging from 58% to 99%. Almost all studies revealed the reduction of statin utilization rate along the follow-up period. The number of statins prescribed was found to be lower among female and elderly patients. CONCLUSION: Despite the established benefits of statin among patients with ACS, our study revealed that statin was underutilized for secondary prevention after ACS. To improve patients’ clinical outcomes with ACS, efforts should be made to increase optimal treatment and compliance with a statin.
No takes yet. Share an insight, caveat, or question.
Dewi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: